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Abstract
Cetuximab and panitumumab, two antibodies targeting the extracellular domain of the epidermal growth factor
receptor (EGFR), are of major clinical importance particularly in the treatment of metastatic colorectal cancer.
As patients may acquire resistance-mediating mutations within the extracellular EGFR domain, functional dissec-
tion of the exact binding sites of EGFR targeting antibodies may help predict treatment responses. We therefore
assessed the epitope recognition of panitumumab by screening phage-displayed random cyclic 7mer and linear
12mer peptide libraries on this antibody. Phage screenings revealed two strong, potentially epitope-mimicking
consensus motifs targeted by panitumumab. A computational approach was used to map the sequences back
to the potential epitope region on domain III of EGFR. The presumed epitope regions (386)WPEXRT(391) and a
biochemically similar though discontinuous region P349-F352-D355 on a neighboring loop of domain III could be
confirmed as part of the functionally relevant binding site of panitumumab by site-directed mutational analysis. To
more accurately differentiate the panitumumab epitope from the previously characterized cetuximab epitope, bind-
ing studies were performed on a broad range of additional mutants. Taken together, this analysis revealed two large,
partially overlapping functional epitopes consisting of 17 critical amino acid positions. Four of these positions were
selectively targeted by cetuximab (I467, S468, Q408, and H409), whereas another four were selectively recognized
by panitumumab (W386, E388, R390, and T391). In view of the clinical significance of extracellular domain muta-
tions, our data may help guide treatment decisions in selected patients receiving EGFR-targeted therapies.
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Introduction
The epidermal growth factor receptor (EGFR) is a major target in
oncology, and monoclonal EGFR antibodies as well as small molecule
tyrosine kinase inhibitors are used as standard treatment for patients
with a variety of solid tumors [1,2]. The most important antibodies
targeting the extracellular domain of the EGFR are the chimeric IgG1
mouse/human antibody cetuximab [3,4] and the fully human IgG2
antibody panitumumab [5]. On binding to EGFR, the antibodies
compete with epidermal growth factor (EGF) binding, inhibit down-
stream pathway signaling, and therefore block proliferation of tumor
cells [6]. While cetuximab has been approved for the treatment of
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colorectal cancer [3,7–9] as well as for head and neck cancer [10,11],
panitumumab has only been approved for its use in colorectal cancer,
so far [12,13]. Yet, recent preliminary data suggest a role for panitu-
mumab in the treatment of patients with human papilloma virus–
negative head and neck cancer [14] and the drug is under investigation
for the treatment of malignant gliomas [15]. In metastatic colorectal
cancer, both antibodies are considered equally effective. Nonetheless,
primary resistance to these targeted agents has been extensively docu-
mented to be mediated by mutations in downstream signaling mole-
cules [16,17]. Of these, KRAS is the only biomarker currently used
in daily practice to select patients with metastatic colorectal cancer
for anti–EGFR-targeted treatment. Other biomarkers such as BRAF,
PIK3CA, PTEN, or NRAS are promising but so far lack enough evi-
dence to be used in the clinics.
The conformational epitope recognized by cetuximab covers a large
surface on domain III of the EGFR [18,19], whereas the exact bind-
ing site of panitumumab remains unclear. Previous studies suggest
that the panitumumab epitope is in close proximity to the cetuximab
epitope or may even partially overlap with the latter [20,21]. How-
ever, there is clear evidence that both epitopes are not identical. This
notion may be supported by the description of effective treatment
with panitumumab in patients after progression under cetuximab
[22,23]. Most convincing data, however, come from a clinical study
showing that a patient with colorectal cancer who acquired a point
mutation under treatment with cetuximab, leading to the substitution
of serine by arginine in position 468 of the extracellular EGFR domain
(denominated 492 by Montagut et al. [24]), developed resistance to
treatment with this antibody, whereas panitumumab was still effective
in this patient. On the molecular level, this corresponded to an abro-
gation of cetuximab binding to the mutated EGFR, while panitumumab
binding remained unaffected. Although extracellular domain mutations
may only account for a small subset of clinically relevant resistance
mechanisms to EGFR-targeted therapies in different tumors, character-
ization of the binding site of panitumumab could help predict the
response to this targeted therapy in selected patients with resistance-
mediating mutations [25].
We therefore explored the epitope recognition of panitumumab
by screening random phage display peptide libraries that provide a
powerful technical platform for epitope mapping of antibodies
[26–30]. Phage display screenings on panitumumab identified a dis-
continuous epitope that overlapped with the large conformational
cetuximab epitope. Our findings could subsequently be confirmed
by mutational analysis and may help guide treatment decisions in
selected patients with domain III EGFR mutations.
Materials and Methods
Phage Display Library Screening
The cyclic 7mer and linear 12mer phage libraries were purchased
from New England Biolabs (Frankfurt, Germany). Three consecutive
screening rounds on panitumumab (Amgen, Thousand Oaks, CA)
were performed with both libraries. Each round started with a
two-fold negative selection on polyclonal IgG (Octapharma, Lachen,
Switzerland), followed by positive selection on panitumumab.Unbound
phage were removed by washing with PBS–Tween 20. Bound phage
were eluted with 0.2 M glycine (pH 2.2) and neutralized with 1 M
Tris-HCl (pH9.0). Eluted phagewere amplified inEscherichia coli strain
K12 ER2738 (New England Biolabs) and purified by polyethylene gly-
col (PEG) precipitation. After three selection rounds, single-phage clones
were amplified and tested for selective binding to panitumumab versus
IgG or cetuximab (Bristol-Myers Squibb, New York, NY) by enzyme-
linked immunosorbent assay (ELISA). Therefore, phage were added
to immobilized panitumumab and detected by an anti-M13, HRP-
conjugated monoclonal antibody (GE Healthcare, Munich, Germany).
ABTS solution (Roche Diagnostics, Grenzach-Wyhlen, Germany) was
used as substrate and the absorption was measured at 405 nm using a
Sunrise microplate reader (Tecan, Männedorf, Switzerland). Selectively
binding phage were sequenced (GATC, Constance, Germany). Phage
displaying the random peptide YMTPPLSSQQKSwere used as control.
Computational Mapping of Epitope-mimicking
Consensus Motifs
The MIMOX algorithm was used to search for similarities between
the phage-displayed consensus motifs and accessible amino acids on the
three-dimensional structure of the EGFR surface [31]. The algorithm is
freely available as a web-based tool (http://immunet.cn/mimox/).
Blocking Assay with Glutathione S -Transferase Fusion Protein
The oligonucleotide encoding the phage-derived peptide IYPPLLRTS-
QAM was amplified from phage DNA by polymerase chain reaction,
digested with BamHI and EcoRI and ligated into pGEX-2TK (GE
Healthcare, Buckinghamshire, England). Glutathione S -transferase
(GST) fusion proteins were expressed in E. coli ER2655 (Invitrogen,
Camarillo, CA), purified following GE Healthcare’s instructions and
used for a phage competition assay as previously described [26,28].
Generation of Human EGFR Mutants
The coding sequence for the human wild-type EGFR was amplified
from cDNA of A431 cells (ATCC, Middlesex, United Kingdom) and
cloned into pBluescript II KS(+) (Fermentas, St Leon-Rot, Germany).
For expression in CHO cells (ATCC, Wesel, Germany), cDNAs
coding for human wild-type EGFR or EGFRvIII (a kind gift from
Dr Hrvoje Miletic) were cloned into pcDNA 3.1+ (Invitrogen). EGFR
mutants with point mutations were generated from cDNA constructs
using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA) as described [32] using individually
designed oligonucleotides. Successful introduction of point mutations
was verified by sequence analysis (Seqlab, Göttingen, Germany).
Flow Cytometry
CHO cells (ATCC, Middlesex, United Kingdom) were main-
tained in RPMI medium and NIH 3T3 cells (ATCC, Middlesex,
United Kingdom) in DMEM medium, both containing 10% FBS
and 1% penicillin/streptomycin. Cell lines were genotypically and
phenotypically tested to confirm identity by the supplier; 5 × 105 CHO
or NIH 3T3 cells were transfected with 15 μg of wild-type or mutant
EGFR vector using polyethylenimine (jetPEI by Polyplus Transfection,
Illkirch, France) according to the manufacturer’s protocol. After 48 hours,
cells were either stainedwith a polyclonal goat anti-humanEGFRantibody
(R&D Systems, Minneapolis, MN) or with panitumumab or cetuximab,
respectively. Secondary antibodies were fluorescein isothiocyanate–labeled
rabbit anti-human (Sigma-Aldrich, St Gallen, Switzerland) or polyclonal
rabbit anti-goat antibodies (Dako Cytomation, Copenhagen, Denmark).
Cells were analyzed on a FACS Calibur (BD Biosciences, Franklin Lakes,
NJ). Data analysis was performed using the FlowJo software 7.6.5 (Tree
Star, Ashland, OR).
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Results
Identification of Epitope-mimicking Peptides by Phage Library
Screenings on Panitumumab
To map the epitope targeted by panitumumab, we screened a cyclic
7mer (CX7C) and a linear 12mer (X12) random peptide phage display
library on this antibody (C, cysteine; X, any amino acid). With both
libraries specifically binding phage could be enriched over several selec-
tion rounds after negative selection on polyclonal IgG. Figure 1A shows
the binding of selected phage pools to panitumumab and control IgG
after each selection round for 7mer phage (left panel) and 12mer phage
(right panel). After the third selection round, single-phage clones were
amplified and their binding was evaluated by ELISA. All selected phage,
but not random control phage, bound specifically to panitumumab as
demonstrated in Figure 1B (7mer phage on the left and 12mer on the
right). Sequencing of their inserts revealed two distinct consensus
motifs (Table 1). While consensus motif I (PXWDXXR) appeared in
both selections, consensus motif II (YPPXXRT) was only displayed by
phage from the 12mer library. To validate that phage binding to pani-
tumumab is mediated by the cognate peptide displayed on the phage
surface, we performed competition assays using a representative phage
peptide as fusion protein to block the phage-panitumumab interaction.
The GST-conjugated peptide IYPPLLRTSQAM inhibited binding of
phage IYPPLLRTSQAM to panitumumab in a dose-dependent man-
ner, whereas GST alone had no effect on phage binding (Figure 1C ).
The Epitope-mimicking Phage Selected on Panitumumab Are
Not Recognized by Cetuximab
As cetuximab binds to a large conformational epitope on domain III
of EGFR that may overlap with the panitumumab epitope, we asked
whether phage clones mimicking the panitumumab epitope were rec-
ognized by cetuximab as well. The binding of one representative phage
clone of each consensus motif was tested on panitumumab, cetuximab,
and control IgG (Figure 1D). Both panitumumab-binding phage
clones did not show any binding to cetuximab, indicating that neither
of the phage-displayed peptides mimics the cetuximab epitope. We
therefore concluded that the epitopes targeted by panitumumab and
cetuximab are not identical. In fact, this lack of cross-reactivity was
expected as entirely unrelated peptides had previously been described
to structurally mimic the cetuximab epitope [33,34]. However, these
data do not exclude a substantial overlap of both epitopes.
Computational Mapping of Panitumumab Epitope-mimicking
Consensus Motifs to EGFR
The MIMOX algorithm was used to search for similarities between
the consensus motifs and accessible amino acids on the three-
dimensional EGFR surface. Whereas the YPP(XX)RT consensus motif
did not yield any results byMIMOXanalysis, the P(X)WD(XX)Rmotif
gave one single hit with high accessibility (198.72 Å2). This consensus
motif was mapped back to the following region: W386-P387-E388-
R390. Interestingly, the identified region belonged to domain III of
the receptor, which—according to previous findings—is the domain
targeted by panitumumab [20]. Figure W1 shows the localization of
the potential epitope region on domain III of EGFR. Although both
distinct consensus motifs could well structurally mimic the same linear
epitope, we also had to consider a discontinuous epitope with critical
amino acids on more than one loop. When manually aligning both
consensus motifs with surface-exposed amino acids on neighboring
loops, further potential homologies were found in spatial proximity to
the previously identified region: P349-F352-D355. The computational
and manual alignments of the epitope-mimicking peptides were there-
fore compatible with a discontinuous epitope targeted by panitumumab.
Mutational Analysis Dissects Functional Panitumumab and
Cetuximab Epitopes on EGFR
To corroborate our findings, we assessed the contribution of each
amino acid to the presumed epitope by mutation to alanine. In the
context of a human EGFR construct for eukaryotic expression, we
mutated the amino acids identified by our phage display screening
(W386A/P387A/E388A, W386A, P387A, E388A, R390A/T391A,
R390A, T391A, P349A/F352A, P349A, F352A, D355A) as sche-
matically displayed in Figure W2. Moreover, we generated eight con-
trol mutants in different parts of domain III, some of them adjacent
to the epitope regions in solvent-accessible surface areas (R353A,
F357A, P362A, V417A, S418A, N420A) and some of them in a dis-
tant part of domain III (G458A/T459A/S460A, K463A/T464A;
Figure W2). Primers used for the mutagenesis reaction are shown
in Table 2. All constructs were transfected into EGFR-negative
CHO cells. Polyclonal EGFR control antibody (used as a probe to
assess proper presentation of EGFR on the surface of transfected
CHO cells) as well as panitumumab and cetuximab binding to trans-
fected CHO cells was then studied by flow cytometry. Transfection
efficiency of the EGFR constructs ranged around 40% of viable cells.
As a lot of mutants exhibited a slightly reduced binding of the mono-
clonal antibodies cetuximab and panitumumab compared to binding
of the polyclonal EGFR control antibody and compared to wild-type
EGFR, we had to specify arbitrary thresholds in binding reduction
defining functionally relevant amino acid positions. A >50% binding
reduction on mutation compared to the binding of polyclonal EGFR
antibody was considered to indicate functionally relevant amino acid
positions (although this threshold was arbitrary and not evaluated
clinically). Positions with reproducibly at least 30% binding reduc-
tion were considered less essential for antibody binding. Positions
that resulted in <30% binding reduction on mutation were not con-
sidered as part of the functional epitope.
All groups of amino acid positions identified by our phage display
analysis—W386A/P387A/E388A, R390A/T391A, P349A/F352A
and D355A—were confirmed to be critical for panitumumab binding
by mutational analysis although R390A/T391A to a lesser extent
[exemplary fluorescence-activated cell sorting (FACS) plots are shown
in Figure 2A]. All of these mutants also exhibited reduced cetuximab
binding, except for R390A/T391A. When we analyzed all single posi-
tions separately, all of these mutants displayed reduced panitumumab
binding; only P349 and T391 proved to be less critical for this inter-
action (Figure 2B ). Some of these single residues also proved to be of
significant relevance for cetuximab binding, especially F352, D355,
and P387 (Figure 2B ). Neither the control mutations adjacent to the
presumed epitope regions nor the distant ones had an impact on pani-
tumumab or cetuximab binding (Figure 2B ). Only control mutation
P362, which is in close proximity to the critical residues, showed a mi-
nor binding reduction of about 40% for both antibodies (Figure 2B ).
EGFRvIII, a clinically relevant EGFR mutant exhibiting a deletion
within domains I and II of EGFR [35], was used as a control. This
deletion mutant showed preserved binding of cetuximab and panitu-
mumab, as expected (Figure 2B).
In addition to the phage display–inspired mutational analysis, we
generated a number of mutants presumably critical for cetuximab
(Q408A/H409A, Q408M/H409E, K443A, K465E, I467M,
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Figure 1. Selection of epitope mimics on panitumumab. (A) Panitumumab binding 7mer (left panel) and 12mer (right panel) phage were
enriched over three selection rounds. Binding of recovered phage pools to panitumumab and control IgG was monitored after each
selection round by measuring bacterial infection. TU, transducing units. (B) Single-phage clones displaying 7mer (left panel) or
12mer (right panel) peptides bind specifically to panitumumab but not to control IgG; 1 × 108 TU of phage displaying the selected
peptides as well as random control phage were incubated on immobilized panitumumab or control IgG. Phage binding was measured
by ELISA. Data are means from triplicate experiments ± SEM. (C) GST-IYPPLLRTSQAM blocks binding of phage IYPPLLRTSQAM to
panitumumab; 1 × 108 TU of phage IYPPLLRTSQAM were incubated on immobilized panitumumab in the presence or absence of
various concentrations of GST-IYPPLLRTSQAM or GST alone. Bound phage were quantified as described in B. Data are means from
triplicate experiments ± SEM. (D) Representative phage selected on panitumumab are not recognized by cetuximab. Phage binding was
measured by ELISA as described in B. Data are means from triplicate experiments ± SEM.
1026 Functional Panitumumab and Cetuximab Epitopes Voigt et al. Neoplasia Vol. 14, No. 11, 2012
S468R, S468I, S468A) [18,19,24,36] or panitumumab (F412A,
I438A) [21] binding to more accurately differentiate between both
epitopes. As expected, Q408 and H409, previously described as
functional core positions within the cetuximab epitope, differentially
affected cetuximab and panitumumab binding on mutation to alanine.
The same applied for I467 on mutation to methionine. Interestingly,
K443A andK465E resulted in a critical binding reduction of both anti-
bodies, thereby adding two additional positions to the functional pani-
tumumab epitope, which had not been suggested by the phage display
analysis. Likewise, mutants F412A and I438A showed a somewhat
reduced binding of both antibodies, although the inhibition ranged
only between 30% and 40%.Mutations of position S468 (denominated
492 by Montagut et al. [24]) showed divergent results, depending
on the amino acid used for replacement. While mutation to arginine
completely abrogated cetuximab binding, as described [24], mutation
to isoleucine showed only a weak binding reduction and an alanine re-
placement did not affect the binding of cetuximab at all. In addition,
panitumumab binding was affected in the S468R mutant, although
to a significantly lesser extent compared to cetuximab. As the interaction
of panitumumabwith this mutant had been described to be comparable
to wild-type EGFR [24], we wished to further corroborate our dis-
cordant finding. Our sequence analysis of the S468R mutant did not
show any additional mutations or deletions within the whole EGFR
gene. In this way, we excluded that genetic aberrations other than
the intentionally introduced point mutation of the target molecule
accounted for reduced panitumumab binding.Moreover, we transfected
the S468R mutant DNA into EGFR-negative NIH 3T3 cells that
had been used for previously published experiments [24]. These
additional transfection experiments resulted in exactly the same anti-
body binding profiles of all three S468 mutants as the transfections into
CHO cells. Likewise, in these experiments, panitumumab binding to
S468R was clearly reduced compared to binding of the polyclonal
EGFR antibody and panitumumab binding to wild-type EGFR, thus
confirming our findings (Figure W3). Figure 2B shows the binding
profiles of all tested mutants.
Finally, we summarized the data generated by phage display and
mutational analysis in a three-dimensional model of the two over-
lapping functional epitopes (Figure 3A ). Four positions differentially
interfering with the binding of panitumumab on mutation are depicted
in red (W386, E388, R390, T391). In mutant T391A, we observed
only very slight differences in cetuximab and panitumumab binding,
but as these differences were amplified in combination with mutant
R390A we considered this position as selectively targeted by panitumu-
mab. Another four positions differentially affecting cetuximab binding
on mutation are depicted in blue (I467, S468, Q408, H409). Nine
residues critical for the binding of both antibodies are shown in light
(>30% binding reduction) and dark (>50% binding reduction) gray.
Both conformational epitopes overlapped with amino acids functionally
characterized as critical for EGF binding (Figure 3B ). This finding
illustrates the underlying mechanism of competitive EGF inhibition
by panitumumab and cetuximab.
Discussion
Targeting the extracellular domain of EGFR with the monoclonal
antibodies cetuximab and panitumumab is a common treatment option
in patients with solid tumors. Resistance has been found to be conferred
by mutations in downstream signaling molecules such as KRAS
[9,17,37]. However, very recently acquired extracellular domain muta-
tions have been shown to mediate resistance to targeted agents as well
[24]. Although little is known so far about the general incidence of such
mutations in different tumors, these new findings put the epitopes of
EGFR targeting antibodies into focus as the antibody binding sites
may help predict responses to therapy in selected patients.
Table 1. Phage-Displayed Peptide Sequences Selected on Panitumumab*.
Amino Acid Sequence of Phage Clone Absolute and Relative Frequency of Phage Clone
Selection of cyclic 7mer phage library
Motif I
C P K W D A A R C 1/9 (11%)
C G P Y T W N S C 1/9 (11%)
C L H R L P I Y C 1/9 (11%)
C P A W D V A R C 1/9 (11%)
C P P W D K L R C 1/9 (11%)
C G P Y T W R S C 1/9 (11%)
C K G G F W H L C 1/9 (11%)
C P A W D H M R C 1/9 (11%)
C P P W D K M R C 1/9 (11%)
Consensus motif I
P X W D X X R
Selection of 12mer phage library
Motif I
A P R D W D V R L M L N 1/10 (10%)
Motif II
I Y P P L L R T S Q A M 3/10 (30%)
A Y P P Y L R S M T L Y 1/10 (10%)
Y P P F Y R T P T K M V 1/10 (10%)
Y P P A E R T Y S T N Y 1/10 (10%)
T Y P P Q L R T E K H L 1/10 (10%)
Y P P A Q R T L M N I D 1/10 (10%)
A F N Y Q M K R D D A R 1/10 (10%)
Consensus motif II
Y P P X X R T
*Sequences are displayed using a single-letter amino acid code.
Table 2. Denomination and Sequences of Mutagenesis Primers*.
Primer Denomination Primer Sequence
S418A CAGTTTTCTCTTGCAGTCGTCGCCCTGAACATAACATCC
G458A/T459A/S450A GGAAAAAACTGTTTGCGGCCGCCGGTCAGAAAACC
R353A CCGGTGGCATTTGCGGGTGACTCCTTCACAC
F357A GGGGTGACTCCGCCACACATACTCCTCC
S468A GGTCAGAAAACCAAAATTATAGCCAACAGAGGTGAAAACAGC
N420A GCAGTCGTCAGCCTGGCCATAACATCCTTGG
V417A CAGTTTTCTCTTGCAGTCGCCAGCCTGAACATAACATCC
K463A/T464A GGGACCTCCGGTCAGGCAGCCAAAATTATAAGC
I438A GGAGATAAGTGATGGAGATGTGGCAATTTCAGGAAAC
P362A CCTTCACACATACTCCTGCTCTGGATCCACAGG
F412A GCAACATGGTCAGGCTTCTCTTGCAGTCGTCAGCC
Q408M/H409E CGCGGCAGGACCAAGATGCAGGGTCAGTTTTCTCTTGC
P349A GATCTCCACATCCTGGCGGTGGCATTTAGGG
K443A GGAGATGTGATAATTTCAGGAAACGCAAATTTGTGCTATGC
P387A GCTGATTCAGGCTTGGGCTGAAAACAGGACGG
K465E GGGACCTCCGGTCAGAAAACCGAAATTATAAGCAACAGAGG
D355A GTGGCATTTAGGGGTGCCTCCTTCACACATAC
P349A/F352A CTCCACATCCTGGCGGTGGCAGCTAGGGGTGAC
F352A CTGCCGGTGGCAGCTAGGGGTGACTCCTTC
S468I GGTCAGAAAACCAAAATTATAATCAACAGAGGTGAAAACAGC
Q408A/H409A CGCGGCAGGACCAAGGCAGCTGGTCAGTTTTCTCTTGC
I467M GGGACCTCCGGTCAGAAAACCAAAATTATGAGCAACAGAGG
S468R GGTCAGAAAACCAAAATTATAAGAAACAGAGGTGAAAACAGC
R390A/T391A GCTTGGCCTGAAAACGCGGCGGACCTCCATGCC
R390A CTTGGCCTGAAAACGCGACGGACCTCCATGC
T391A CCTGAAAACAGGGCGGACCTCCATGCCTTTG
W386A/P387A/E388A GCTGATTCAGGCTGGGGCTGCAAACAGGACGGACC
W386A GCTGATTCAGGCTGGGCCTGAAAACAGGACG
E388A GATTCAGGCTTGGCCTGCAAACAGGACGGACC
*All primers are designed in a 5′-3′ orientation. Only forward primers are shown; corresponding
reverse primer sequences are complementary reverse. Base exchanges are underlined.
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We therefore mapped the binding site of panitumumab by phage dis-
play library screenings and confirmed our findings bymutational analysis.
In this way, we defined a functional epitope targeted by panitumumab,
which substantially overlapped with the previously identified cetuximab
epitope on domain III of EGFR. As our mutational analysis comprised a
total of 30 mutants covering almost all surface accessible amino acid
positions in the critical part of EGFR domain III, this analysis may pro-
vide a comprehensive picture of both functional epitopes.
Our data need to be discussed in the context of previously pub-
lished work. So far, there has been only limited knowledge about the
Figure 2. Mutational analysis of EGFR reveals functionally critical amino acid positions of the conformational epitopes of panitumumab
and cetuximab. (A) Exemplary flow cytometry analysis of mutants W386A/P387A/E388A, P349A/F352A, D355A, and R390A/T391A.
EGFR-negative CHO cells were transfected with wild-type EGFR or mutations thereof. Binding of panitumumab, cetuximab, or a control
polyclonal EGFR antibody was assessed by FACS analysis 48 hours after transfection. FSC, forward scatter. (B) Evaluation of 30 mutants
reveals the extent of the functional panitumumab and cetuximab epitopes. Flow cytometry experiments on transfected CHO cells were
performed as in A. Data are shown as relative values compared to EGFR-positive cells (percentage of EGFR-positive cells set to 1) and
are means of duplicate experiments ± SEM.
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epitope targeted by panitumumab. In line with our findings, how-
ever, the cross-blocking experiments by Dechant et al. [20] suggested
that panitumumab and cetuximab bind to EGFR in close spatial
proximity. Freeman et al. [21] describe several amino acid positions
as critical for panitumumab binding: P349, D355, F412, and I438.
While our phage display analysis also suggested that P349 and D355
may be part of the panitumumab epitope and our alanine mutational
analysis clearly confirmed these two residues as critical positions, the
mutation of F412 and I438 to alanine only resulted in a 30% to
40% abrogation of panitumumab as well as cetuximab binding to
mutated EGFR in our hands. We therefore considered positions
F412 and I438 less critical for the binding of both antibodies. Because
D355 is involved in binding of the EGF to its receptor, the identi-
fication of D355 as part of the panitumumab epitope is especially
meaningful as it may provide the molecular basis for the mechanism
of action of this antibody. Thus, the experimentally observed compe-
tition of panitumumab with EGF [6] can be explained by an overlap of
binding sites.
Our work also adds some new aspects to the functional definition
of the previously identified cetuximab epitope. This epitope has been
studied intensively by several groups both in a structural and in a
functional way. The crystal structure of the EGFR-cetuximab com-
plex revealed that the epitope covers a large surface on domain III of
the EGFR [18]. Moreover, some functionally critical residues, such
as Q384, Q408, H409, K443, K465, I467, and S468, have been
identified by different groups [18,19,24,36]. By selective alanine
scanning, we identified some more residues in two regions of EGFR
domain III (F352, D355, P387), which are apparently involved in
cetuximab binding as well, as their mutation results in an abrogation
(>50%) of antibody binding to EGFR. Positions P349, P362,W386,
E388,R390, F412, and I438 seem to be of some minor importance for
the EGFR-cetuximab interaction as their mutation results in a binding
reduction of 30% to 50%.
In most of our mutants, alanine replacement was used as it rep-
resents a standard technical tool for mapping of functional epitopes
[38]. This amino acid is usually chosen as it does not impose con-
formational changes and extreme electrostatic or steric effects. In
some specific cases, we generated mutants with alternative replace-
ment mutations, if these had been well characterized previously. In
this context, we noticed that some residues are not significantly
impacted by mutation to alanine compared to substitutions with
other amino acids. Whereas the clinically relevant mutation of serine
in position 468 to arginine results in a complete abrogation of
cetuximab binding, the substitution of the same residue with iso-
leucine only results in a partial binding inhibition and the replace-
ment with alanine does not significantly alter the binding of
cetuximab at all [24,36]. Vice versa, in positionD355, the mutation
to alanine results in a loss of cetuximab binding in our hands, whereas
Figure 2. (continued).
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the substitution with threonine [18] does not produce this effect.
Likewise, our data indicated that the mutation of positions S418 and
R353 to alanine does not impair antibody binding although these
residues are part of the structurally defined binding site of cetuximab
[18]. These findings nicely demonstrate the complexity of epitope
definition, taking into account the structural as well as the functional
dimension of the binding site, which are known to show imperfect
congruence [39].
From a clinical perspective, this complexity may impede the pre-
diction of resistance to antibody-based EGFR targeting. Residues
defined as critical for cetuximab or panitumumab binding by an
alanine scanning approach may well be mutated in vivo to other
amino acids without functional consequences. Therefore, even if
the binding site has been functionally defined in vitro by mutational
analysis, every unrecognized domain III mutation occurring in an
individual tumor sample would have to be tested in vitro for func-
tional consequences to more reliably predict the response to therapy.
Likewise, we currently lack a biologically meaningful in vitro binding
threshold, allowing us to estimate if a given mutation will result in a
clinically relevant abrogation of antibody binding in vivo. While a
complete binding abrogation in vitro (as found for cetuximab bind-
ing to S468R) will most likely result in clinical ineffectiveness of the
antibody (at least in the tumor subclone harboring the mutation), it
remains unclear what clinical consequences will arise from mutations
inducing only partial impairment of antibody binding. In this context,
it is quite interesting to note that in our hands panitumumab binding
to the S468R mutant was reduced to 30%, although the antibody has
been described to be active in tumors harboring this mutation [24].
Taken together, we functionally defined the conformational epitope
targeted by panitumumab within domain III of the EGFR, thereby
Figure 3. Three-dimensional model of the functional panitumumab and cetuximab epitopes. (A) Functional dissection of panitumumab
and cetuximab epitopes. Amino acid positions critical for panitumumab binding are shown in red and for cetuximab in blue. Residues
critical for the binding of both antibodies are shown in shades of gray (light gray, >30% binding reduction; dark gray, >50% binding
reduction). (B) Overlap of panitumumab and cetuximab epitopes with EGF binding site. The left panel shows the panitumumab epitope
in red and the EGF binding site in yellow. The overlapping amino acids are depicted in orange. In the right panel, the cetuximab epitope
is depicted in blue, the EGF binding site is depicted in yellow, and the overlapping amino acid positions are shown in green (pani.,
panitumumab; cetuxi., cetuximab).
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differentiating it from the cetuximab epitope. These data are of clinical
relevance as they may help predict which patients with EGFR domain
III mutations may benefit from cetuximab or panitumumab treatment
and may therefore guide treatment decisions in selected patients.
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Figure W1. Computational modeling of potential panitumumab epi-
tope using phage-displayed peptides. The P(X)WD(XX)R motif was
mapped back to the three-dimensional EGFR structure using the
MIMOX algorithm. The presumed panitumumab epitope is shown
in black.
Figure W2. Generation of EGFR mutants. Localization of mutated amino acid positions on three-dimensional model of EGFR domain III.
Left, middle, and right panels show different views on EGFR domain III.
Figure W3. Mutational analysis of position S468. Position S468
was mutated to alanine, isoleucine, and arginine. After transfec-
tion into NIH 3T3 cells, binding of panitumumab and cetuximab
as well as polyclonal EGFR antibody was studied by flow cytom-
etry. Data are shown as relative values compared to EGFR-positive
cells (percentage of EGFR-positive cells set to 1) and means of trip-
licate experiments ± SEM.
